An cire abin da ke ƙasa daga rahoton Pfizer na 2021 2nd sakamakon kwata. Yana nufin ribar kamfani kan siyar da abin da aka fi sani da shi a duk duniya a matsayin rigakafin "Pfizer" Covid-19 ko, bisa ga sunan kimiyya, BNT162b2.
Bayanin da aka haskaka shima yana nan a cikin wasu rahotannin samun kuɗi na Pfizer. Shi ne, wato, Pfizer ya raba riba akan tallace-tallace 50-50 tare da ainihin mai haɓakawa da mai samfurin: kamfanin Jamus BioNTech.
Wannan yana nufin cewa babban mai cin gajiyar kuɗi daga siyar da allurar "Pfizer" shine ainihin BioNTech. Ta yaya idan aka raba 50-50? To, ban da kashi 50% na ribar da aka samu akan tallace-tallacen da aka yiwa alama Pfizer, bisa ga sharuɗɗan sa. hadin gwiwa tare da Pfizer, BioNTech kuma yana yin tallace-tallace kai tsaye a cikin yankuna biyu da aka keɓe (Jamus da Turkiyya), kuma, ƙari ga haka, yana da wata yarjejeniya ta daban tare da Fosun Pharma yana ba da tabbacin (bisa ga ta). wakiltar kansa ga SEC) Kashi 30 zuwa 39 na ribar da ake samu kan tallace-tallace a kasar Sin. (Don rashin izini, na ƙarshe ya zuwa yanzu an iyakance shi ga Hong Kong kawai.)
Amma idan ribar BioNTech akan siyar da allurar “Pfizer” ta fi ta Pfizer kwata-kwata, ribarta. gefe ne nisa, nisa mafi girma. Wannan saboda yayin da BioNTech ke samun kashi 50% na ribar da aka samu akan siyar da alamar Pfizer, ba ta raba farashin masana'anta da tallace-tallacen. Kashi 50% na sarauta ne. Wannan ya bayyana yawan ribar da BioNTech ta samu a shekarar 2021 kafin harajin kashi 79%! Duba ginshiƙi na ƙasa daga BioNTech's 2021 F-20 yin rajista zuwa SEC. Sama da Euro biliyan 15 a cikin ribar da aka samu akan kusan Euro biliyan 19 na kudaden shiga, kwatankwacin alkaluman daloli a halin yanzu. Lura kuma cewa BioNTech ya biya kusan kashi ɗaya bisa uku na waɗannan Yuro miliyan 15 a matsayin harajin kamfani a Jamus. BioNTech bai taɓa yin kasuwanci da wani samfur ba. Don haka, kusan duk ribar da take samu suna da alaƙa da rigakafin “Pfizer”.
Duk daya Rahoton kudi Pfizer Inc da aka ambata a sama kiyasin Pfizer na kansa ribar riba kafin haraji - ko kuma a nan Gefen Kuɗi Kafin Haraji (IBT) - akan siyar da allurar kamar yadda yake a cikin "high-20s" (shafi na 4). Don haka, ribar BioNTech akan siyar da maganin “Pfizer” ya kai kusan sau uku fiye da na Pfizer.
Bugu da ƙari, idan muka raba bambance-bambancen kuma muka ce ribar Pfizer kafin haraji shine kashi 27.5% kuma muka yi amfani da wannan ribar ga cikakken rahoton Pfizer na kudaden shiga na shekara ta 2021 akan tallace-tallace na BNT162b2 na kusan dala biliyan 37, muna samun babban riba akan tallace-tallace na kusan dala biliyan 10. (Don cikakken shekarar Pfizer na kudaden shiga na 2021 akan tallace-tallace na BNT162b2, duba shafi na 35 na ƙarshen rahoton Pfizer na shekara nan. An gano samfurin a matsayin "Comirnaty.")
Ribar da BioNTech ta samu kan siyar da allurar rigakafin “Pfizer” ta kai kusan kashi 50% fiye da ribar Pfizer: dala biliyan 15 (ko Yuro) zuwa biliyan 10.
Don haka, a takaice, me yasa aka fi mai da hankali sosai kan Pfizer a cikin tattaunawar jama'a game da kasuwar rigakafin Covid, kusan ban da BioNTech har ma da tattaunawa ta kwararrun manazarta kudi?
Tabbas, me yasa har ma ake kiran samfurin da ake magana da shi maganin "Pfizer"? Wannan ba shakka kuskure ne. Alurar rigakafi ce ta BioNTech (zaton alurar riga kafi ne). BioNTech ya haɓaka kuma a zahiri yana da shi. Don haka, lambar sunan kimiyya: BNT162b2. Pfizer kawai kera da siyar da shi a wasu kasuwanni (amma ba duka) a madadin BioNTech ba.
BioNTech kuma ita ce ta dauki nauyin shahararrun gwaje-gwajen asibiti da suka kai ga ba da izinin maganin. Ana nuna wannan, alal misali, akan duk takaddun FDA masu dacewa. Pfizer ya gudanar da gwaje-gwajen, duk da haka kuma, a madadin BioNTech. Kuma BioNTech ita ce mai ba da izinin tallace-tallace a kowace kasuwa inda Pfizer ke siyar da samfur, haka kuma, ba shakka, kamar yadda yake kan kasuwannin da aka keɓe. Kuma, a ƙarshe, BioNTech shine, kamar yadda aka nuna a sama, ya zuwa yanzu babban mai cin gajiyar kuɗi na kasuwancin samfurin.
Wannan ba batun “Semantic” bane kawai. Muna bukatar mu ambaci abubuwa daidai don fahimtar su daidai. Tsananin mayar da hankali kan Pfizer, har ya kai ga cewa BioNTech ya kusan bace, a tsakanin sauran abubuwa, ya haifar da ruɗi na ikon duniya na Pfizer da kuma karkatar da hankali daga masu aikin gwamnati: musamman, Jamus, wanda, kamar yadda aka nuna dalla-dalla a labarina na Brownstone na farko. nan, ya dauki nauyin rigakafin BioNTech kuma yana da babban sha'awar tattalin arziki ga nasarar duniya na samfur da kamfani.
Tabbas, kamar yadda aka tattauna a wannan labarin, gwamnatin Jamus ta dauki nauyin sosai kafa na BioNTech a matsayin wani ɓangare na shirin ba da tallafi na "Go-Bio" wanda ainihin manufarsa ita ce sanya Jamus ta zama jagora a fasahar kere-kere.
Kamar yadda hakan ke faruwa, ba tare da sanin yawancin masu sa ido ba, Jamus kuma ta kasance mai nisa kuma ta kasance babban mai ba da gudummawar rigakafin rigakafin cutar ta WHO na Covid-19 na duniya. A ƙasa, alal misali, akwai ginshiƙi wanda ke nuna manyan masu ba da gudummawa ga kasafin kuɗin COVID-2020 na WHO na 19 (SPRP).
Kamar yadda ake iya gani a ƙasa, 2021 ba ta bambanta sosai ba.
Amma wannan labari ne na wani lokaci…
-
Robert Kogon shi ne sunan alkalami na wani ɗan jarida da ake bugawa da yawa wanda ke yin rubuce-rubuce kan al'amuran Turai.
Duba dukkan posts
